Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report sent to investors on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $11.88 on Thursday. The firm has a market cap of $15.68 million, a price-to-earnings ratio of -0.98 and a beta of 0.61. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32.

Insider Activity at Palvella Therapeutics

In other news, Director George M. Jenkins bought 4,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was purchased at an average price of $12.93 per share, with a total value of $51,720.00. Following the transaction, the director now directly owns 180,671 shares in the company, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.39% of the stock is owned by company insiders.